Amoneta Diagnostics at 2024 Clinical Trials on Alzheimer's Disease (CTAD)

Introducing our Research on Advancing Alzheimer’s Disease Stratification

We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference.

During the second poster session on October 31st, we will present our poster number 00492, which introduces an innovative approach to Alzheimer’s patient stratification by combining “static” genetic data from our APO-Easy® and NeuroDeGene® genotyping tools, with dynamic biomarker signatures through AI algorithms.

Our research, integrating APOE genotyping, suggests that this combined methodology has the potential to not only improve patient stratification accuracy but also lay the groundwork for more effective and personalized Alzheimer’s treatments. This approach represents a crucial step forward in the quest to combat Alzheimer’s disease, offering hope for more targeted and impactful clinical interventions.

CTAD is the premier forum for researchers, clinicians, and industry experts to discuss the latest developments in Alzheimer’s treatment and prevention. We are excited to share our findings with the global scientific community and to collaborate with others who are equally committed to finding solutions for this devastating disease.

Amoneta is launching a global non-profit initiative focused on enhancing the characterization of dementia patients. 50,000 patients with cognitive impairment and dementia will undergo comprehensive genetic profiling utilizing the next-generation targeted sequencing tool, NeuroDeGene®, which encompasses over 15,000 genetic variants, including the APOE ε4 variant recently suspected to be a new genetic form of AD disease. Individuals with APOE ε4 homozygosity, as well as those with other less well-known genetic abnormalities, may benefit from tailored prevention strategies and treatment trials.

Visit our poster on October 31 (number 00492) to learn more about our findings and discuss the future of Alzheimer’s research with our team.